Rapamycin inhibits peritoneal fibrosis by modifying lipid homeostasis in the peritoneum.
Jing Liu(Nanjing Medical University), Miao Zhang(Nanjing Drum Tower Hospital), Qingyan Zhang(University of South China), Wei Zhu(Ministry of Education of the People's Republic of China), Bo Jin(Fudan University), Pengfei Xu(Nanjing Drum Tower Hospital), Yuan Feng, Chunming Jiang(Qilu University of Technology), Yangyang Xia(National Clinical Research)
PubMed
January 1, 2019
Cited by 14
Related Papers
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
Cation exchanged MOF-derived nitrogen-doped porous carbons for CO<sub>2</sub>capture and supercapacitor electrode materials
|Journal of Materials Chemistry A|2017|169
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168
UiO-66-Coated Mesh Membrane with Underwater Superoleophobicity for High-Efficiency Oil–Water Separation
|ACS Applied Materials & Interfaces|2018|150